Sicca syndrome following immune checkpoint inhibition.

Mavragani, Clio P; Moutsopoulos, Haralampos M

Mavragani, Clio P; Moutsopoulos, Haralampos M.

Affiliation

Mavragani CP; Departments of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Athens Academy, Chair Medical Sciences/Immunology, Greece. Electronic address: kmauragan@med.uoa.gr.
Moutsopoulos HM; Departments of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Athens Academy, Chair Medical Sciences/Immunology, Greece.

Clin Immunol ; 217: 108497, 2020 08.

Article in En | MEDLINE | ID: mdl-32531346

Subject(s)

Immune Checkpoint Inhibitors/adverse effects; Ipilimumab/adverse effects; Nivolumab/adverse effects; Sjogren's Syndrome/chemically induced; Aged; Autoantibodies/blood; Autoantibodies/drug effects; CD4-Positive T-Lymphocytes/cytology; CD4-Positive T-Lymphocytes/immunology; Humans; Immune Checkpoint Inhibitors/therapeutic use; Ipilimumab/therapeutic use; Male; Neoplasms/drug therapy; Nivolumab/therapeutic use; Sjogren's Syndrome/immunology

Key words

Differential diagnosis; Immune checkpoint inhibitors; Sicca syndrome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sjogren's Syndrome / Ipilimumab / Nivolumab / Immune Checkpoint Inhibitors Type of study: Risk_factors_studies Limits: Aged / Humans / Male Language: En Journal: Clin Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2020 Type: Article

Fulltext

XML

PubMed Links

Search on Google